This is great news but shouldn't it put some sort of ceiling on the price in the short term around the exercise prices of the warrants and convertible preferreds?
Do these prefereds pay a dividend? I gather at least that it's not a cumulative preferred.
The stock price speaks for itself. OXBT should never have been listed and has been a fraud from the very beginning. The last piece of news to finally make OXBT get delisted is BAD TRIAL news.....which will likely be released very soon.
FDA approval for Focalin XR expected for this Quarter...GL
This Low float Stock awaiting 8 FDA approvals and has another 2 Potential Blockbusters ready for Phase 3
Foclian XR alone which is Partnered with Par Pharma will drive IPCI deep into Profitability quickly after Market Launch .There is NO generic version of Focalin XR available on the Market , IPCI & Par will be the first here and its normal that the first generic takes 30%-40% of market share quickly after launch .
5-6 FDA approvals expcted within 12 months .This Gem has everything to move into Double Digits the Market Cap of $40 Million is a Big Joke .
Market Cap:$ 42 M
Cash : $3 M
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercial launch of the product by Par .
I would agree with soundsgood02. TBI is a huge issue for our military and if oxycyte wasn't promising, they never would have invested the $.
Yes, TBI is a huge issue for the MIL.
However, the money the MIL has "invested" in OXBT is little more than a rounding error on the Pentagon's annual office supplies budget.
Moreover, if this company has so much potential, why is the stock down 90% in the last year?
...for a ultra micro cap like this ,it's a huge investment...similar to the entire market cap...
..Oxygen Biotherapeutics, Inc., (OXBT) a developer of oxygen-carrying therapeutics, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) results from two series of animal studies designed to address Agency concerns regarding the use of Oxycyte in treating traumatic brain injury (TBI) patients. These studies were conducted to probe both the interactions between Oxycyte and the immune system as well as assess the PFC-based emulsion’s potential to increase the risk of intracerebral hemorrhage (ICH). This research was funded as part of a $2.07 million grant that Oxygen Biotherapeutics has with the U.S. Army who is committed to developing treatments for TBI. Submission of these data represents an important step forward in responding to FDA questions and adding US clinical sites to those already participating in the development of Oxycyte
You clowns watched and did nothing as the PPS fell from a high of almost $61.00 to $1.36 today.
And now that OXBT trades pennies above its all-time low, the "plan" now is to do.... what? Pump out meaningless PRs?
Do you fools seriously believe the investment community is going to ever again take a chance in investing money in your failed company? Take a look at the result of today's press release: OXBT is not *up* today - it's down.
And OXBT is down today because - again - the investment community clearly realizes there's ZERO reason to buy this stock.
This is what happens when a company is "managed" by an incompetent, Missing in Action Board of Directors. The BOD has clearly not cared about OXBT for a long, LONG time; as a result, why should anyone else?
The stock price weakness is a clear indication this stock is headed to $0.00 and a delisting...after the FDA finally rejects the latest OXBT Scam efforts. SELL!!!
Will the people ostensibly running this so-called company EVER deliver ANYTHING of substance that results in the stock going up?
And I'm not talking about lame update press releases, or "news" about submitting long overdue studies to the FDA.
How many times does this company need to deal with a potential delisting notice before they get clued into the fact that positive and substantive news about the company's products are the ONLY thing that will EVER result in stock price appreciation?
Instead, however, shareholders are given dilutive financing news, or reverse split news, or conference attending "news" for years and years and years.
None of these people should be overseeing a publicly traded company, as they simply do NOT understand how to provide a return on investment to shareholders.
OXBT - down yet again today.
This stock has fallen so far, for so long, that the investment community no longer cares, or trusts, anything the people running this company says or does.
Patent news? Meaningless. Nonclinical study news? Meaningless.
Management diddled and fumbled for days and weeks and months on end while the stock lost 25% of its value. Then 50%, 75%, 90%, and then 95%.
Pull up a one year chart on OXBT here on Yahoo, then take a look at the bottom right hand side of the chart. As of today, OXBT is down 88.87% over the past year.
In fact, click on *any* of the available timeframes on the chart. 1 day, 5 day, 1 month, six months, five years, Max - they all have one thing in common: they all show OXBT *not* as a gain, but rather at a loss.
Every. Single. Chart.
This is what happens when incompetent, non-market savvy people run a publicly traded company.